The company’s stock rose significantly after it announced the full Phase I/II data. Image credit: Lightspring / Shutterstock.com. Intensity Therapeutics’ stock has risen nearly 400% after its oncology ...
In a Phase I trial, biomarkers seem to suggest the potential for a once or twice yearly dosing of Wave’s siRNA for weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback